The 30th European Hematology Association Congress (EHA 2025) will take place in Milan, Italy, from June 12–15, 2025. As one of the world’s most influential hematology conferences, EHA 2025 will bring together leading experts, researchers, and industry leaders to discuss the latest advances in diagnosis, treatment, and research on hematologic diseases. Chidamide (Epidaza®), an innovative therapy developed by Chipscreen Biosciences, will be featured in 19 studies at the congress, including 11 poster presentations and 8 online abstracts spanning multiple therapeutic areas. Poster presentation details:

 

T-cell lymphoma (TCL) 1 study

 

Study title: Chidamide in combination with azacitidine, mitoxantrone liposomes, and prednisone (CAMP regimen) for treatment-naïve TFH-derived peripheral T-cell lymphoma.

Abstract No.: PS1975

 

B-cell lymphoma (BCL) 4 studies

 

01

Study title: Novel ZCR (zanubrutinib, chidamide, rituximab) ± CHOP regimen demonstrates promising efficacy in frontline treatment of double-expressor diffuse large B-cell lymphoma (DE-DLBCL)

Abstract No.: PF922

 

02

Study title: Chidamide in combination with anti-CD20 monoclonal antibody plus CHOP for treating newly diagnosed B-cell non-Hodgkin lymphoma with epigenetic mutations: preliminary analysis from a phase II study.

Abstract No.: PS1888

 

03

Study title: Molecular subtype-guided targeted therapy combined with R-MINE (R-MINE+X) in relapsed/refractory diffuse large B-cell lymphoma: a single-arm, open-label, multicenter phase II study.

Abstract No.: PF932

 

04

Study title: A phase II study of dual epigenetic modulation with obinutuzumab/liposomal mitoxantrone in chemoresistant DLBCL patients post-salvage therapy.

Abstract No.: PF953

 

Acute myeloid leukemia & myelodysplastic syndromes (AML&MDS) 2 studies

 

01

Study title: Efficacy and safety of VAC (venetoclax, azacitidine, chidamide) reinduction treatment for unfit acute myeloid leukemia patients failed to respond to one cycle of VA induction.

Abstract No.: PS1532

 

02

Study title: Chidamide monotherapy prevents the relapse of high-risk myeloid malignancies post-allo-HSCT: a prospective, single-center, phase I/II trial.

Abstract No.: PS2032

 

Acute lymphoblastic leukemia (ALL) 1 study

 

Study title: Venetoclax, tucidinostat, pegaspargase, and dexamethasone induction regimen for newly diagnosed adult ETP-ALL: a chemotherapy-free, low-toxicity, effective regimen.

Abstract No.: PS1386

 

Basic research 3 studies

 

01

Study title: Novel role of chidamide in TAM reprogramming and immunotherapy enhancement through RNA splicing.

Abstract No.: PF998

 

02

Study title: Chidamide enhances CD7 CAR T-cell efficacy in T-cell lymphoma through epigenetic CD7 upregulation and mitochondrial apoptosis pathway engagement.

Abstract No.: PF1008

 

03

Study title: Synergistic efficacy of HDACI chidamide with GL-V9 by suppressing MYBL2 expression in acute myeloid leukemia.

Abstract No.: PF462

 

Chidamide-related studies cover a wide range of hematologic malignancies—from the CAMP regimen in treatment-naïve TFH-TCL, to ZCR±CHOP combination therapy in double-expressor DLBCL, from dual epigenetic modulation in chemotherapy-resistant patients to chemotherapy-free induction regimens in ETP-ALL. These investigations explore cutting-edge scientific areas, including tumor microenvironment reprogramming, RNA splicing regulation, and enhancement of CAR-T efficacy, delivering safer and more effective “China Solutions” through post-transplant maintenance and cross-target synergy breakthroughs.